Cas:313527-66-1 4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol manufacturer & supplier

Chemical Name:4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol

CAS.NO:313527-66-1

Synonyms:4-amino-2-(5-methyl-benzooxazol-2-yl)-phenol

Molecular Formula:C₁₄H₁₂N₂O₂

Molecular Weight:240.25700

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:72.28000

Exact Mass:240.09000

LogP:3.67220

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-amino-2-(5-methyl-benzooxazol-2-yl)-phenol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-amino-2-(5-methyl-benzooxazol-2-yl)-phenol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-amino-2-(5-methyl-benzooxazol-2-yl)-phenol Use and application,4-amino-2-(5-methyl-benzooxazol-2-yl)-phenol technical grade,usp/ep/jp grade.

Related News: Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself. 4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol manufacturer Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. 4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol supplier Common signs of infection include respiratory symptoms, fever, cough, shortness of breath and breathing difficulties. In more severe cases, infection can cause pneumonia, severe acute respiratory syndrome, kidney failure and even death. 4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol vendor Standard respiratory support therapies are used to treat the symptoms and wait for the virus to be cleared by itself. 4-Amino-2-(5-methyl-benzooxazol-2-yl)-phenol factory The unit of the British drugmaker, which is challenging HIV drug market leader Gilead Sciences, said it will work with the FDA to determine the next steps for the new drug application.